Market closed
Kyverna Therapeutics/$KYTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Ticker
$KYTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
112
ISIN
US5019761049
Website
KYTX Metrics
BasicAdvanced
$92M
-
-$3.33
-
-
Price and volume
Market cap
$92M
52-week high
$17.55
52-week low
$1.78
Average daily volume
253K
Financial strength
Current ratio
8.609
Quick ratio
8.472
Long term debt to equity
1.614
Total debt to equity
3.092
Interest coverage (TTM)
-1,004.25%
Management effectiveness
Return on assets (TTM)
-46.93%
Return on equity (TTM)
-80.74%
Valuation
Price to book
0.35
Price to tangible book (TTM)
0.35
Price to free cash flow (TTM)
-0.701
Growth
Earnings per share change (TTM)
-96.29%
3-year earnings per share growth (CAGR)
-67.75%
What the Analysts think about KYTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.
KYTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KYTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KYTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kyverna Therapeutics stock?
Kyverna Therapeutics (KYTX) has a market cap of $92M as of May 10, 2025.
What is the P/E ratio for Kyverna Therapeutics stock?
The price to earnings (P/E) ratio for Kyverna Therapeutics (KYTX) stock is 0 as of May 10, 2025.
Does Kyverna Therapeutics stock pay dividends?
No, Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Kyverna Therapeutics dividend payment date?
Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) does not currently have a Beta indicator.